rss
Sex Transm Infect 2006;82:201 doi:10.1136/sti.2005.018960
  • Reviews

COMMENTARY

  1. E J Adams1,
  2. K M E Turner2
  1. 1Modelling and Economics Unit, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London, UK; elisabeth.adams@hpa.org.uk
  2. 2Imperial University, London, UK

      How much does chlamydia screening cost and is it worth introducing? That is, will the savings from future disease averted offset the screening costs (will it be cost saving?), and if it will not, is the extra health “bought” by screening worth it, in terms of alternative uses of the same resources? Here, Roberts et al1 provide a valuable critique of the literature on the cost effectiveness of chlamydia screening. Despite a large body of published work, their paper highlights the lack of appropriate methods used in the majority of previous studies.

      To correctly model the full effects of screening for an infectious disease like chlamydia (including …

      [Full text of this article]

      This Article

      1. Extract
      2. Full text
      3. PDF

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.